What’s Propelling Cytrx Corporation (NASDAQ:CYTR) After Higher Shorts Reported?

January 17, 2018 - By Marguerite Chambers

 What’s Propelling Cytrx Corporation (NASDAQ:CYTR) After Higher Shorts Reported?

Investors sentiment increased to 0.73 in 2017 Q3. Its up 0.15, from 0.58 in 2017Q2. It increased, as 13 investors sold CytRx Corporation shares while 9 reduced holdings. 5 funds opened positions while 11 raised stakes. 12.29 million shares or 4.56% less from 12.87 million shares in 2017Q2 were reported.
Miracle Mile Ltd reported 0% in CytRx Corporation (NASDAQ:CYTR). Massachusetts-based Geode Capital Mngmt Ltd Com has invested 0% in CytRx Corporation (NASDAQ:CYTR). Commercial Bank Of Montreal Can stated it has 490 shares. 750 are held by Valley National Advisers. Virtu Financial Ltd Company stated it has 148,710 shares or 0% of all its holdings. Deutsche Commercial Bank Ag accumulated 0% or 10,806 shares. Susquehanna Intll Gp Llp accumulated 0% or 40,691 shares. California Public Employees Retirement Sys holds 0% or 133,307 shares in its portfolio. Guggenheim Capital Limited Co reported 0% of its portfolio in CytRx Corporation (NASDAQ:CYTR). The Kansas-based Creative Planning has invested 0% in CytRx Corporation (NASDAQ:CYTR). National Bank Of Mellon, New York-based fund reported 70,370 shares. Clear Harbor Asset Mgmt Ltd Com invested in 0% or 13,000 shares. Wells Fargo And Company Mn holds 0% or 14,756 shares in its portfolio. Blackrock Inc holds 0% in CytRx Corporation (NASDAQ:CYTR) or 1.42 million shares. Bnp Paribas Arbitrage Sa holds 0% of its portfolio in CytRx Corporation (NASDAQ:CYTR) for 4 shares.

The stock of Cytrx Corporation (NASDAQ:CYTR) registered an increase of 5.19% in short interest. CYTR’s total short interest was 2.36 million shares in January as published by FINRA. Its up 5.19% from 2.24M shares, reported previously. With 306,100 shares average volume, it will take short sellers 8 days to cover their CYTR’s short positions. The short interest to Cytrx Corporation’s float is 2.25%.

The stock decreased 6.35% or $0.12 during the last trading session, reaching $1.77. About 297,197 shares traded. CytRx Corporation (NASDAQ:CYTR) has declined 78.08% since January 17, 2017 and is downtrending. It has underperformed by 94.78% the S&P500.

CytRx Corporation operates as a biopharmaceutical research and development firm specializing in oncology. The company has market cap of $48.92 million. The companyÂ’s product candidate is the aldoxorubicin, which is in Phase III clinical trial as a therapy for patients with soft tissue sarcomas whose tumors have progressed following treatment with chemotherapy; in Phase IIb clinical trial in small cell lung cancer; in Phase II clinical trial in HIV-related Kaposi's sarcoma; in Phase II clinical trial in patients with late-stage glioblastoma (brain cancer); in Phase Ib trial in combination with ifosfamide in patients with STS; and in Phase Ib trial in combination with gemcitabine in subjects with metastatic solid tumors. It currently has negative earnings. It also has completed Phase IIb and Phase Ib/II clinical trials with aldoxorubicin as a first-line therapy for STS; a Phase Ib clinical trial of aldoxorubicin in combination with doxorubicin in patients with advanced solid tumors; and a Phase Ib pharmacokinetics clinical trial in patients with metastatic solid tumors.

More notable recent CytRx Corporation (NASDAQ:CYTR) news were published by: Prnewswire.com which released: “CytRx Corporation Files Definitive Proxy Statement for Upcoming Special Meeting” on August 30, 2017, also Prnewswire.com with their article: “CytRx Corporation Announces Filing of Key Provisional Patent Applications for …” published on December 06, 2017, Seekingalpha.com published: “Derivative Action Seeks To Benefit Nominal Defendant CytRx Corporation” on September 07, 2017. More interesting news about CytRx Corporation (NASDAQ:CYTR) were released by: Prnewswire.com and their article: “CytRx Corporation Announces Amendment to Definitive Proxy Statement for …” published on September 13, 2017 as well as Prnewswire.com‘s news article titled: “CytRx Corporation Announces Results from Special Meeting of Stockholders” with publication date: October 27, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.